Baxter to establish $200M venture arm

Baxter International is looking to invest in early-stage companies whose offerings complement its existing portfolio of medical products. It will invest up to $200 million in such companies through Baxter Ventures. "As the company's internal capabilities have advanced our late-stage pipeline, we have the capacity to further accelerate the early-stage development of essential therapies," Robert Parkinson, Jr., chairman and CEO of Baxter, said in a statement.  Baxter release | Story

Suggested Articles

Seven developers will provide digital health solutions aimed at the COVID-19 pandemic, including smartphone apps, wearables and big data programs.

Illumina will drop $8 billion to reacquire its former spinout, which after nearly five years is nearing completion of its cancer-seeking blood test.

The CE Mark for the system’s fourth iteration follows a July 2019 approval from the FDA.